This site is best viewed with JavaScript enabled.

AlloMap®: A Non-Invasive, Test Service for Heart Transplant Patients

AlloMap is the only non-invasive blood test with a rapid turnaround that helps physicians identify the absence* of heart transplant rejection

  • Provides Healthcare Providers with important information: Quantifiable, objective, and reproducible test results
  • Offers convenience for patients: Only requires a routine blood draw
  • Is widely used and accepted: Over 56,000 tests have been performed and successfully used in the post-transplant care of more than 13,000 patients by physicians at more than 120 medical centers

*Absence is defined here as the very low probability of moderate/severe acute cellular rejection as measured by the negative predictive value. AlloMap test results are only to be used in conjunction with standard clinical assessment.

AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. Indicated for use in patients: 15 years of age or older and at least 2 months (≥ 55 days) since transplantation.